While several different interventions exist for contraception, there aren’t yet a full array of options for HIV prevention. Choices matter. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
Prevention Paradigm, 2017-beyond
The South Africa PrEP Story: What “starting out” looks like
This graphic charts how many people in South Africa tested as HIV negative each month vs. how many people commenced oral PrEP from month-to-month. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
Target Tracking, 2010–2020
Calculating progress toward the UNAIDS Fast Track Goals is complex but ambitious targets are the best kind. AVAC has long argued they propel action even if they aren’t met. But when it comes to achieving epidemic control, progress must be properly calculated, and can never be confused with success. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
Timeline for DAIDS HIV Trials Network Recompetition
This graphic looks ahead from 2017 through 2027 at the DAIDS HIV Trials Network Recompetition process. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
The UNAIDS 10-Point Plan for Making Progress on Prevention
The UNAIDS 10-point plan for making progress on prevention omits elements of the “research-to-rollout” continuum, and leaves the definition of prevention out—focusing on the “how” rather than the “what”. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
US Public Sector Investment in HIV Prevention R&D, Compared to All Other Funding, 2012–2016
This graphic tracks US public sector investment in HIV prevention research & development vs all other funding sources over the four year period of 2012-2016. For much more on HIV prevention research & development funding, visit www.hivresourcetracking.org.
Driving Product Introduction and Access
AVAC has always advocated for closing critical prevention gaps. Now we’re taking our mission further. With African and global partners, we’re stepping beyond advocacy to generate the knowledge and tools that countries need to more quickly deliver new advances.
We’re engaging directly with national decision-makers to identify and overcome delivery hurdles for PrEP. We’re examining the preferences and experiences of people at high risk for HIV, so that future tools—long-acting injectables, vaginal rings and others—can be optimized to meet their needs.
AVAC Report 2017: Mixed messages and how to untangle them
AVAC is excited to share our annual “state of the field” report on biomedical prevention research and implementation. AVAC Report 2017: Mixed Messages and How to Untangle Them is straight talk about today’s complex context for HIV prevention. Read this report if you’ve wondered that there’s more rhetorical support than ever for HIV prevention but no more money? How can the world be “on the path to epidemic control” while human rights are trampled in many places, and rates of HIV diagnoses climb in others? How can scientists be so sure they know what women want, without doing research to find out?
For more from the report, including a link to all its graphics, visit avac.org/report2017.
Px Wire October-December 2017, Vol. 10, No. 4
In Px Wire, we preview part of the AVAC Report 2017, which includes a set of recommendations and priorities that keep funding and research crossing-cutting, strategic and responsive to people’s real-world needs. Check out the infographic, which provides a visual history of the DAIDS Networks and a look at what’s proposed for the next funding cycle.
An Advocate’s Guide to the DAIDS Trial Networks Funding Recompetition Process
This factsheet lays out for advocates how funding decisions under discussion at the US Division of AIDS (DAIDS) could impact communities all over the world. Read on to learn how advocates can help shape the current funding discussion and how the DAIDS process works, for future reference.